78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 2018
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 2018
SUMMARY
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Binding immunoglobulin protein (BiP) or 78 kDa glucose-regulated protein (GRP-78) is a protein encoded by HSPA5 gene. It plays a role in facilitating the assembly of multimeric protein complexes inside the endoplasmic reticulum. It is involved in the correct folding of proteins and degradation of misfolded proteins via its interaction with DNAJC10.
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.
The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Immunology which include indications Lung Cancer, Pancreatic Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Esophageal Cancer, Gastric Cancer, Glioma, Melanoma, Pancreatic Ductal Adenocarcinoma, Rheumatoid Arthritis and Solid Tumor.
The latest report 78 kda Glucose Regulated Protein - Pipeline Review, H2 2018, outlays comprehensive information on the 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Binding immunoglobulin protein (BiP) or 78 kDa glucose-regulated protein (GRP-78) is a protein encoded by HSPA5 gene. It plays a role in facilitating the assembly of multimeric protein complexes inside the endoplasmic reticulum. It is involved in the correct folding of proteins and degradation of misfolded proteins via its interaction with DNAJC10.
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.
The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Immunology which include indications Lung Cancer, Pancreatic Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Esophageal Cancer, Gastric Cancer, Glioma, Melanoma, Pancreatic Ductal Adenocarcinoma, Rheumatoid Arthritis and Solid Tumor.
The latest report 78 kda Glucose Regulated Protein - Pipeline Review, H2 2018, outlays comprehensive information on the 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5)
- The report reviews 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted therapeutics and enlists all their major and minor projects
- The report assesses 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Overview
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Companies Involved in Therapeutics Development
Intezyne Inc
Nuevolution AB
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Drug Profiles
HA-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IT-139 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rasolvir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Target TPI-1 and GRP-78 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GRP78 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Dormant Products
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Product Development Milestones
Featured News & Press Releases
Apr 16, 2018: Intezyne To Showcase Novel Cancer Resistance Pathway Inhibitor IT-139'S Potential In Gastric Cancer At ChinaBio Partnering Forum 2018 In Suzhou, PRC
Apr 13, 2018: Data Showing that IT-139 Triggers Immunogenic Cell Death (ICD) to Be Presented at AACR 2018 Annual Meeting
Apr 10, 2018: Combination of Checkpoint Inhibitors and Intezyne's Novel Cancer Resistance Pathway Inhibitor IT-139 Shows Enhanced Immune Efficacy
Mar 22, 2018: Data on Cancer Resistance Pathway Inhibitor IT-139 to be Presented at AACR 2018 Annual Meeting
Jun 20, 2017: Intezyne Technologies Granted Orphan Drug Designation for IT-139 in Pancreatic Cancer
Mar 31, 2017: Intezyne Technologies Announces Presentation on IT-139 at AACR Symposium
May 24, 2012: Niiki Pharma To Present Final Phase I Clinical Data On Anti-Cancer Agent, NKP-1339 At Annual Meeting Of ASCO 2012
Feb 15, 2012: Niiki Pharma's New Compound Found To Be Promising Against Cancer
Feb 01, 2012: Niiki Pharma Forms Scientific Advisory Board, To Focus On Anti-cancer Compound NKP-1339
Jan 17, 2012: Niiki Pharma Completes Phase I Dose Escalation For First-In-Man Anti-Cancer Agent, NKP-1339
Nov 15, 2011: Niiki Pharma Reports On Synergistic Activity Of New Anti-Cancer Agent NKP-1339 With Other Anti-Cancer Agents
Sep 20, 2011: Niiki Pharma Announces Positive Interim Data From Ongoing Clinical Trial Of Anti-Cancer Agent NKP-1339
Jun 01, 2011: Niiki Pharma To Present Interim Data From Phase I Study Of NKP-1339 At ASCO
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Overview
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Companies Involved in Therapeutics Development
Intezyne Inc
Nuevolution AB
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Drug Profiles
HA-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IT-139 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rasolvir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Target TPI-1 and GRP-78 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GRP78 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Dormant Products
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Product Development Milestones
Featured News & Press Releases
Apr 16, 2018: Intezyne To Showcase Novel Cancer Resistance Pathway Inhibitor IT-139'S Potential In Gastric Cancer At ChinaBio Partnering Forum 2018 In Suzhou, PRC
Apr 13, 2018: Data Showing that IT-139 Triggers Immunogenic Cell Death (ICD) to Be Presented at AACR 2018 Annual Meeting
Apr 10, 2018: Combination of Checkpoint Inhibitors and Intezyne's Novel Cancer Resistance Pathway Inhibitor IT-139 Shows Enhanced Immune Efficacy
Mar 22, 2018: Data on Cancer Resistance Pathway Inhibitor IT-139 to be Presented at AACR 2018 Annual Meeting
Jun 20, 2017: Intezyne Technologies Granted Orphan Drug Designation for IT-139 in Pancreatic Cancer
Mar 31, 2017: Intezyne Technologies Announces Presentation on IT-139 at AACR Symposium
May 24, 2012: Niiki Pharma To Present Final Phase I Clinical Data On Anti-Cancer Agent, NKP-1339 At Annual Meeting Of ASCO 2012
Feb 15, 2012: Niiki Pharma's New Compound Found To Be Promising Against Cancer
Feb 01, 2012: Niiki Pharma Forms Scientific Advisory Board, To Focus On Anti-cancer Compound NKP-1339
Jan 17, 2012: Niiki Pharma Completes Phase I Dose Escalation For First-In-Man Anti-Cancer Agent, NKP-1339
Nov 15, 2011: Niiki Pharma Reports On Synergistic Activity Of New Anti-Cancer Agent NKP-1339 With Other Anti-Cancer Agents
Sep 20, 2011: Niiki Pharma Announces Positive Interim Data From Ongoing Clinical Trial Of Anti-Cancer Agent NKP-1339
Jun 01, 2011: Niiki Pharma To Present Interim Data From Phase I Study Of NKP-1339 At ASCO
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Intezyne Inc, H2 2018
Pipeline by Nuevolution AB, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Intezyne Inc, H2 2018
Pipeline by Nuevolution AB, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Intezyne Inc
Nuevolution AB
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Intezyne Inc
Nuevolution AB
